128 filings
8-K
FPRX
Five Prime Therapeutics, Inc.
16 Apr 21
Completion of Acquisition or Disposition of Assets
8:38am
8-K
FPRX
Five Prime Therapeutics, Inc.
15 Apr 21
Other Events
4:41pm
8-K
FPRX
Five Prime Therapeutics, Inc.
4 Mar 21
Amgen to Acquire Five Prime Therapeutics for Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class
8:58am
8-K
FPRX
Five Prime Therapeutics, Inc.
15 Jan 21
Results of Operations and Financial Condition
5:00pm
8-K
FPRX
Five Prime Therapeutics, Inc.
15 Jan 21
Other Events
10:06am
8-K
cdo1j5yy5 x0g4z04821
17 Nov 20
Five Prime Announces Closing of Upsized Public Offering of Common Stock
5:05pm
8-K
2gt973pcgd4d1i h9t1
13 Nov 20
Five Prime Announces Pricing of Upsized Public Offering of Common Stock
5:06pm
8-K
h8pib c36mjyxe4
10 Nov 20
Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates
5:19pm
8-K
c9yrhx9ru7bct lqrae
3 Nov 20
Five Prime Therapeutics Reports Third Quarter 2020 Results
4:10pm
8-K
1hbwcnbpllw9qm4ndh2s
2 Nov 20
Five Prime to Present First Pre-clinical Data of Anti-CCR8 Antibody FPA157
5:11pm
8-K
1cc6sozet oj1
4 Sep 20
Entry into a Material Definitive Agreement
12:00am
8-K
rr8h3g
1 Sep 20
Departure of Directors or Certain Officers
6:07am
8-K
sfuvg dq83pqacp
6 Aug 20
Five Prime Therapeutics Reports Second Quarter 2020 Results
4:31pm
8-K
v578ax4lc e66r7o0
20 May 20
Submission of Matters to a Vote of Security Holders
4:06pm
8-K
7l53lb48 be0hs
7 May 20
Five Prime Therapeutics Reports First Quarter 2020 Results
4:10pm
8-K
oc7njfo
17 Apr 20
Departure of Directors or Certain Officers
4:09pm
8-K
27g mln7wzw075er7i7
14 Apr 20
Five Prime Therapeutics Appoints Tom Civik as Chief Executive Officer
9:06am
8-K
khpop33q2i
27 Feb 20
Five Prime Therapeutics Reports Fourth Quarter and Full Year 2019 Results
4:11pm
8-K
g4zg1o07q
26 Feb 20
Departure of Directors or Certain Officers
4:05pm
8-K
izszlfe837bk86c
18 Feb 20
Five Prime Therapeutics Provides Update on Phase 2 Trial of Cabiralizumab Combined with Opdivo® in Pancreatic Cancer
9:28am